ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Unicycive Therapeutics Inc

Unicycive Therapeutics Inc (UNCY)

0.405
0.007
( 1.76% )
Updated: 15:06:17

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.405
Bid
0.4002
Ask
0.4199
Volume
1,424,838
0.39 Day's Range 0.42
0.339 52 Week Range 1.818
Market Cap
Previous Close
0.398
Open
0.40
Last Trade
3
@
0.40995
Last Trade Time
15:06:10
Financial Volume
$ 570,631
VWAP
0.400488
Average Volume (3m)
1,017,532
Shares Outstanding
37,606,630
Dividend Yield
-
PE Ratio
-0.48
Earnings Per Share (EPS)
-0.84
Revenue
675k
Net Profit
-31.41M

About Unicycive Therapeutics Inc

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other ... Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Unicycive Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker UNCY. The last closing price for Unicycive Therapeutics was $0.40. Over the last year, Unicycive Therapeutics shares have traded in a share price range of $ 0.339 to $ 1.818.

Unicycive Therapeutics currently has 37,606,630 shares outstanding. The market capitalization of Unicycive Therapeutics is $14.97 million. Unicycive Therapeutics has a price to earnings ratio (PE ratio) of -0.48.

UNCY Latest News

Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)

LOS ALTOS, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease...

Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease...

Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE...

Unicycive Therapeutics Joins Russell Microcap® Index

LOS ALTOS, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.051-11.18421052630.4560.4640.37526471090.41231254CS
4-0.0879-17.83323189290.49290.5670.33918806590.45235852CS
12-0.755-65.08620689661.161.210.33910175320.55739984CS
26-0.578-58.79959308240.9831.8180.3396784320.8000603CS
52-0.825-67.07317073171.231.8180.3393933640.79905207CS
156-2.555-86.31756756762.963.940.3397232961.61257631CS
260-8.145-95.26315789478.558.730.3397593781.81178193CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUZENuZee Inc
$ 3.4299
(233.00%)
120.34M
SLNASelina Hospitality PLC
$ 0.0532
(104.62%)
1.11B
DRMADermata Therapeutics Inc
$ 2.40
(84.62%)
60.72M
PIRSPieris Pharmaceuticals Inc
$ 14.60
(82.96%)
5.14M
QXOQXO Inc
$ 122.00
(53.85%)
183.37k
NXTTNext Technology Holding Inc
$ 2.4399
(-58.08%)
881.87k
NUWENewellis Inc
$ 2.50
(-39.76%)
925.6k
VWEVintage Wine Estates Inc
$ 0.07
(-37.44%)
30.98M
LITMSnow Lake Resources Ltd
$ 0.6525
(-32.59%)
5.37M
ATPCAgape ATP Corporation
$ 0.14515
(-32.49%)
6.45M
SLNASelina Hospitality PLC
$ 0.053
(103.85%)
1.11B
SGMOSangamo Therapeutics Inc
$ 0.5573
(38.87%)
227.28M
NVDANVIDIA Corporation
$ 115.08
(-6.13%)
214.51M
SQQQProShares UltraPro Short QQQ
$ 9.02
(10.27%)
155.17M
TSLATesla Inc
$ 219.281
(-11.00%)
130.99M

UNCY Discussion

View Posts
rosemountbomber rosemountbomber 7 minutes ago
Not sure where I saw it but I thought the company said it has funds to fund operations thru 2026.
👍️0
Whalatane Whalatane 18 minutes ago
Cash Position: As of March 31, 2024, cash and cash equivalents totaled $48.9 million.

So that should carry them until the Senate decides on the Kidney Patient act .
Act pass's this Co has a future ...if it doesn't ...another small biotech bites the dust
JMO
Kiwi
👍️0
Whalatane Whalatane 34 minutes ago
RMB. As I previously posted . I was disappointed with the trial results ...in particular the fact that close to 50% were OK with their current pho lowering drugs ...which are mostly cheap generics . Previously the opinion was that 80 % or greater hated their current meds.
So the potential market is smaller then I thought.
Given that the Co is low on cash ( IIRC ) and a reverse split is inevitable ....this stock is not appealing ....except for the potential upside if the Kidney Patient act pass's.
If this act pass's MD's will be free to bill Medicare for the new oral pho lowering drugs from ARDX and UNCY ( when UNCY final has their OLC on the market ) for a couple of years at least ....by them being kept out of the dialysis bundle .

While neither ARDX.s Xphazoh or UNCY's OLC are likely to be major sellers ...they both will find niche market shares largely dependent on their pricing .
The dialysis patients that have issues with constipation will want Xphazoh and those used to taking Fosrenol will find the switch to OLC fairly easy ....provided both have low copays .

This position only works IF the Kidney Patient act pass's
JMO
Info only
Kiwi
👍️0
Whalatane Whalatane 56 minutes ago
Great Point partners ....disclose 9.99% position
http://archive.fast-edgar.com/20240718/AN2ZRG2CZ22C2ZE2222M2ZO2QQ82ZZ22N262/

Kiwi
👍️0
rosemountbomber rosemountbomber 57 minutes ago
Thanks Kiwi. This certainly can’t hurt. Hopefully the negative sentiment with this stocks means that there is potential for upside.
👍️0
Whalatane Whalatane 1 hour ago
True face plant ? With that sentiment maybe its time to buy into this a s a spec on the Kidney Patient Act passing
https://sewell.house.gov/2024/3/rep-sewell-s-kidney-patient-act-passes-out-of-the-house-ways-and-means-committee

This will be a high risk speculative trade that I think I'll put on .
Info only ...NOT investment advice
Kiwi
👍️0
molee molee 5 days ago
I think this now qualifies as a true "faceplant" ...
👍️0
CosmicSamurai92 CosmicSamurai92 5 days ago
Oh,it's a final flush alright. Wish I never bought this. I will hold tho.
AoN.
👍️0
molee molee 2 weeks ago
Hopefully a final flush there on pretty high volume ... We'll see .
👍️0
Whalatane Whalatane 2 weeks ago
Uruguay vs Colombia ...OMG. Sunday will be a big soccer day .
Inflation data tomorrow

Kiwi
👍️0
ErnieBilco ErnieBilco 2 weeks ago
It gives me hope that my decision to add at these lows will payoff.

HC Wainwright, in my opinion, push failures which gives me some warm and fuzzies.

See you over a buck at least.
👍️0
Whalatane Whalatane 2 weeks ago
HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $4.5 Price Target....FWIW today

Kiwi
👍️0
Whalatane Whalatane 2 weeks ago
Thx. Need to watch that game . A key catalyst ( also for ARDX ) will be if the Kidney Patient Act pass's...approved by the house and now before the Senate ...passage by EOY hopefully .
Re OLC. they may prefer it but are they willing to pay the Brand label price for it ....we'll have to see how they price it once approved.
Co ( and my wife who prescribes to dialysis patients ) always maintained that the patients hate the current pho lowering drugs . So I was surprised to learn in their trial anyway ...49% were satisfied with the current meds
Started a position in FULC recently ...P 3 data in Q4. U might want to chk out
Kiwi
👍️0
rosemountbomber rosemountbomber 2 weeks ago
I meant to add Kiwi that I realize what you are saying in that with 49% satisfied with their current therapy it might minimize market potential to start with, but with education they can indicate that of those who tried OLC 79% preferred it and it might behoove someone to at least try it, even if they are satisfied with current therapy they more than likely will end up preferring OLC if they try it.

What a convoluted post, Sorry. Typed this while frantically watching England defeat the Netherlands in Euro 2024 semis. That is a tough job, because their opponents are stacked - Netherlands, Holland, the Dutch.
👍️0
rosemountbomber rosemountbomber 2 weeks ago
They may have been satisfied with prior therapy but 79% preferred OLC.
👍️0
Whalatane Whalatane 2 weeks ago
Thx for the info .
Being the Debbie Downer that I am ....what I didn't like was while 49% were satisfied with their prior therapy.

The prior therapy most were on is the generic Renvela ....which is cheap ......so there goes half the market potential .
Of the 51% that weren't satisfied with their prior therapy ...how many are willing to pay for Brand OLC ?

Theres also a suspicion that the Co is using these upgrades to sell stock / raise funds ....either way they need to get the PPS over $1 or face a Naz delisting by EOY.
Theres probably a market for OLC provided the Kidney Patient Act pass's ....just not as large as I'd hoped for .
JMO
Kiwi
👍️0
ErnieBilco ErnieBilco 2 weeks ago
6 analysts moved UNCY up to outperform
👍️0
molee molee 2 weeks ago
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy –

– Median daily pill burden reduced by half after switch to OLC –

LOS ALTOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the initial results from the patient reported outcome survey conducted during the UNI-OLC-201 pivotal clinical trial. The positive top-line results from the oxylanthanum carbonate (OLC) trial in patients with hyperphosphatemia who have chronic kidney disease on dialysis were reported on June 25, 2024.

The patient reported outcomes are being evaluated from a satisfaction questionnaire that was a pre-specified exploratory objective of the study. The questionnaire surveyed patients in the UNI-OLC-201 trial to assess characteristics of their current phosphate binder as compared to OLC after switching medications. The questions included patient satisfaction, ease of use, and preferred therapy and were taken at the start and conclusion of the study. In the survey, OLC consistently outperformed the other phosphate binders in all categories: 79% of patients preferred OLC while 18% preferred their prior therapy, 98% of patients said that OLC was easy to take compared to 55% for their prior therapy, 89% of patients said they were satisfied with OLC while 49% were satisfied with their prior therapy.

“We are gratified by the encouraging patient reported findings from our pivotal trial that mirror the better-than-expected topline clinical results that we reported last month,” said, Shalabh Gupta, MD, Chief Executive Officer of Unicycive. “In the design of our pivotal clinical trial for OLC, we believed that it was important to consider the patient perspective and the personal challenges that they face in managing their hyperphosphatemia. Importantly, the results showed that patients preferred OLC greater than 4 to 1 over their prior phosphate binder therapy. Our focus is now directed toward filing our New Drug Application and making OLC available to patients who may benefit from its potential best-in-class profile, if approved.”

Pablo Pergola, MD, PhD, Research Director, Clinical Advancement Center, Renal Associates, P.A., and principal investigator for the UNI-OLC-201 trial, commented, “In this clinical study, our patients stated a clear preference for OLC over their prior phosphate lowering therapies. This positive patient reported experience with OLC is encouraging because hyperphosphatemia outcomes are often negatively impacted by non-adherence to phosphate lowering prescriptions due to side effects and high pill burden. At the end of the study, several of my patients asked not to be put back on their prior phosphate binder.”

Background

Patients screened to enter the trial were taking the following phosphate binder therapies (n=128): 52% Renvela® (sevelamer carbonate), 19% PhosLo® (calcium acetate, 15% Auryxia® (ferric citrate), 13% Velphoro® (sucroferric oxyhydroxide, and 1% Other. Once patients were enrolled into the trial, they went through a washout period for two weeks to clear their current phosphate binder from the body.

Key Findings

Preferred Therapy: In response to the question: Based on your experience in this clinical trial, do you prefer your current phosphate binder or OLC, 79% preferred OLC, 18% preferred their prior phosphate binder, and 3% preferred neither.

https://ml.globenewswire.com/Resource/Download/9a233ce4-0844-4e63-b22e-650fa9d140b6/image3.png

Ease of Use: In the trial, the median patient pill burden on OLC was reduced by half compared to their prior phosphate binder therapy. The pill burden on prior therapy at screening was a median of 6 (mean 6.5) pills per day. On OLC, the pill burden at the end of the study was a median of 3 (mean 3.9) pills per day.

In response to the question: My current phosphate binding medication is easy to take, 55% of patients agreed, 41% disagreed, and 4% neither agreed nor disagreed. In response to the question: Oxylanthanum carbonate (OLC) is easy to take, 98% of patients agreed, 1% disagreed, and 1% neither agreed nor disagreed.

https://ml.globenewswire.com/Resource/Download/39ea3031-e96f-488a-9212-331b53aa376f/image4.png

Patient Satisfaction: At screening, less than half of the patients in the study agreed with the statement, I am satisfied with my current phosphate binder medication. At the end of the study and after switching to OLC, 89% of patients agreed with the statement, I am satisfied with oxylanthanum carbonate. Only 6% expressed dissatisfaction with OLC.

https://ml.globenewswire.com/Resource/Download/1f4d052e-09f9-4043-bc89-b34cdc87ddcc/image5.png

The initial findings from the Oxylanthanum carbonate (OLC) pivotal trial satisfaction questionnaire are preliminary and subject to change based on further detailed analysis. Full survey results are expected to be presented at a future medical conference.
👍️0
Whalatane Whalatane 2 weeks ago
OT. for those interested ...EWTX EDG-750 P1 data due Q3 chk that board for more details
UNCY and ARDX ---watch for passage of the Kidney Patient act ...currently before the Senate
Kiwi
👍️0
ErnieBilco ErnieBilco 3 weeks ago
Looks like most sellers are bailing out or will hold less than 1% while there are 5 funds that are selling a little but maintaining their 9.99% stakes so that equates to still having 50% institutional holding shares.
👍️0
molee molee 3 weeks ago
Do we have any idea what those shares cost the owners ?

Company will still have to raise money it seems .
👍️0
rosemountbomber rosemountbomber 3 weeks ago
Are you seeing the price at 45 cents?

Thanks for posting by the way.
👍️0
Whalatane Whalatane 3 weeks ago
04:19 PM EDT, 07/05/2024 (MT Newswires) -- Unicycive Therapeutics ( UNCY ) on Friday filed a registration statement for the potential sale of up to 50 million shares by selling stockholders from time to time.
The company won't receive any proceeds from the sale of shares.

In case you're wondering why the PPS is down 9%
Kiwi
👍️0
molee molee 3 weeks ago
$UNCY ... Found on Fidelity :

BRIEF-Unicycive Therapeutics Entered Into First Amendment To Manufacturing & Supply Agreement With Shilpa Medicare
REUTERS - 4:21 PM ET 7/2/2024
INVESTMENT NEWS
Email Facebook. Twitter. LinkedIn. Print
July 2 (Reuters) - Unicycive Therapeutics Inc ( UNCY ):

* UNICYCIVE THERAPEUTICS ( UNCY ): ENTERED INTO FIRST AMENDMENT TO MANUFACTURING & SUPPLY AGREEMENT WITH SHILPA MEDICARE

* UNICYCIVE THERAPEUTICS ( UNCY ): UNDER AMENDMENT, CO TO MAKE BINDING PURCHASE ORDER FOR TABLETS OF OLC, SHILPA AGREED TO DELIVER SUCH ORDER BY JUNE 30 2025

* UNICYCIVE THERAPEUTICS ( UNCY ): ALSO AGREED TO ORDER ADDITIONAL TABLETS FOR DELIVERY BETWEEN DEC 31, 2025 & JUNE 30, 2026

* UNICYCIVE THERAPEUTICS ( UNCY ): AGREED TO PROVIDE CERTAIN FUNDING TO SHILPA FOR NEW MANUFACTURING LINE Source text for Eikon: Further company coverage:
👍️ 1
Whalatane Whalatane 3 weeks ago
Aside from other issues ...The Kidney Care Act is looming large for all Co's selling new dugs to the dialysis population ...see my posts on ARDX which had a melt down today
👍️0
Whalatane Whalatane 3 weeks ago
Big sell off in a lot of biotechs due to Bidens USA today article about expanding Medicare negotiations for up to 50 drugs .
PBM's drive the cost of drugs in the US ...needs to address that
Kiwi
👍️0
rosemountbomber rosemountbomber 3 weeks ago
This (49 cents) might be it. Not very big volume.
👍️0
molee molee 3 weeks ago
How far down will "they" push it this time ???
👍️0
Whalatane Whalatane 3 weeks ago
Well some forced buying as its going into the micro cap fund ...and theres also this
BENZINGA
12:12 PM ET Jun-25-2024
HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (UNCY.NaE) with a Buy and maintains $4.5 price target.

Kiwi
👍️0
rosemountbomber rosemountbomber 3 weeks ago
More than average volume after only 1 hour.
👍️ 1
sethjohn911 sethjohn911 4 weeks ago
I sold that little pop for profit so i got some loss back, I will only trade this in and out till we get close to PDUFA they need more money so I expect them to give shares away and cash the price like the always do.
👍️0
Whalatane Whalatane 4 weeks ago
Well U called that right on ....short covering , dead cat bounce ...whatever does the trick
Kiwi
👍️0
sethjohn911 sethjohn911 4 weeks ago
Picked up a few today, think this is just too over done, it's still a huge drug and NDA is supposed to be here sooner than later according to CC call they had. But I am glad I stopped out when I did, or I would have lost a huge amount of cash, should get a dead cat bounce here.
👍️0
rosemountbomber rosemountbomber 4 weeks ago
This business of 106 enrolled down to 71 evaluable patients in the study. So I still have not been able to listen to the Q&A to see if that question was answered, but looking at a slide presentation, makes me a little less concerned.

106 were enrolled, but they all had to go through a washout period that lasted up to 3 weeks. At the end of this period, only those whose serum phosphate levels were over 5.5 were then titrated. Those whose serum phosphate levels remained below 5.5 were considered "washout failures" and were not permitted to proceed in the trial. See page 12:

https://d1io3yog0oux5.cloudfront.net/_15f6b57fd286e47b8a141ca0970ba257/unicycive/db/1912/17749/pdf/OLC+201+Topline+Data+Presentation+-+Final+-+6.25.24+.pdf
👍️0
molee molee 4 weeks ago
Since you mentioned it , I checked :

"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 20, 2024, stockholders of Unicycive Therapeutics, Inc. (the “Company”) approved an increase to the number of authorized shares of the Company’s common stock from 200,000,000 shares to 400,000,000 shares as set forth in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 20, 2024. On June 21, 2024, the Company filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State to increase its authorized shares of common stock from 200,000,000 shares to 400,000,000 shares."


https://www.otcmarkets.com/filing/html?id=17645573&guid=jXO-knJPBAGaJth
👍️ 1
rosemountbomber rosemountbomber 4 weeks ago
Appreciate it
👍️0
Whalatane Whalatane 4 weeks ago
RMB. Sorry to hear
Kiwi
👍️0
rosemountbomber rosemountbomber 4 weeks ago
Tried this morning and couldn’t get it to work. Frustrating. Last couple of hours in the middle of shocking news of the sudden death of wife’s very close friend and co-worker back in Fl. No information as to what happened and we are thinking it had to be something sudden like HA or aneurysm. 61 years old.
👍️0
Whalatane Whalatane 4 weeks ago
Did you find out the reasons why 106 patients were enrolled , but only 71 evaluated ?
Figure these patients are getting the med for free during the trial .....2 wks wash out then 4 wks ? on OLC ...but they lose roughly 25% of the enrollment during this short period ??? Raises questions on market acceptance assuming FDA approval.

I did see a tweet ( X ) that they intended to double the existing share count ...which I assume means a 50 % dilution .....not sure how reliable that info is.

Did U ever get the Q & A part of the CC working to listen to ? Q&A's is usually the only part I find worth listening to on CC's

RLZT ...insider open market purchase today I think

Kiwi
PS. post by Ernie on the ARDX board says UNCY doubled the share count
👍️0
rosemountbomber rosemountbomber 4 weeks ago
Yeah I did find that to be a rather incredulous statement, but I guess that means that he also can’t figure out the reason for this beating, so just uses the standard go-to profit taking
👍️0
molee molee 4 weeks ago
"Profit-taking" ??? Who the hell is he kidding ???
👍️0
rosemountbomber rosemountbomber 4 weeks ago
Saw this on another board so can’t vouch for accuracy but no reason to not believe:

“Maxim Group analyst Jason McCarthy maintained a Buy rating on Unicycive Therapeutics) yesterday and set a price target of $4.00.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding the performance and potential of Unicycive Therapeutics’ oxylanthanum carbonate (OLC). The positive results from the UNI-OLC-201 pivotal trial, demonstrating the safety and tolerability in patients with chronic kidney disease (CKD), exceeded expectations. Despite a recent drop in UNCY shares, which McCarthy attributes to profit-taking, the impressive trial outcomes suggest a strong case for FDA approval and subsequent filing in the third quarter of 2024. These developments, along with the drug’s potential to become a leading phosphate binder, provide a solid foundation for the Buy rating. Moreover, McCarthy’s optimism is bolstered by OLC’s performance in studies, notably outperforming fosrenol with a lower discontinuation rate due to adverse events. With approximately 90% phosphate control achieved in trial participants, OLC’s efficacy is evident. Additionally, the drug’s formulation as easy-to-swallow tablets positions it competitively in the market, potentially enabling it to capture significant market share from current treatments. McCarthy’s analysis suggests that OLC’s approval could disrupt the phosphate binder landscape, which underpins the positive outlook for Unicycive Therapeutics’ stock.”
👍️0
molee molee 4 weeks ago
$UNCY has now hit a new 52 week low ...
😔 1
Whalatane Whalatane 4 weeks ago
RMB. I've listened to plenty of CC's on Safari and never had this problem . Not a good day for them to have this kind of screw up .
Kiwi
👍️0
rosemountbomber rosemountbomber 4 weeks ago
Well I can't get it to work either. Won't load at all in Safari and in Chrome it works for 10 seconds and then says not supported. Frustrating. I often say, technology not ready for prime time.
👍️0
Whalatane Whalatane 4 weeks ago
Well there are reasons for warrant holders to short a stock after all

Warrant holders might short a stock for several strategic reasons:
Hedging: Warrant holders may short the underlying stock to hedge their position. This strategy can protect against potential losses if the stock price declines. By shorting the stock, they can offset the loss in the value of the warrants with gains from the short position.

Arbitrage Opportunities: If the warrants are deep in the money and the stock price is expected to remain stable or decline, warrant holders might short the stock to lock in a risk-free profit. This involves shorting the stock and using the proceeds to exercise the warrants, thereby covering the short position at a lower cost.

Leverage and Gearing: Warrants provide significant leverage, meaning small changes in the stock price can lead to larger percentage changes in the value of the warrants. By shorting the stock, warrant holders can take advantage of this leverage to amplify their returns, especially if they anticipate a decline in the stock price.
Market Sentiment: If warrant holders believe the stock is overvalued or expect negative news that could drive the stock price down, they might short the stock to profit from the anticipated decline. This speculative strategy can be risky but potentially lucrative if their market predictions are accurate.

Early Exercise and Forced Sales: In some cases, such as with Special Purpose Acquisition Companies (SPACs), warrants might be called for early exercise. If warrant holders expect this and believe the stock price will drop after the warrants are exercised, they might short the stock to benefit from the expected decline.
These strategies involve significant risk and require careful consideration of market conditions and the specific terms of the warrants.


Kiwi
👍️ 1
Whalatane Whalatane 4 weeks ago
Why would the warrant holders short it ?
I think the warrants had an exercise price of $1 .....so If market had ramped the PPS to $2 on the trial results , the warrant holders could have exercised their $1 warrants ( bought the stock issued by Co for $1 even tho existing stock was trading at $2 ) ...essentially doubling their money and also flooding the Co with cash reducing the risk of a capital raise.
Not an expert on warrants but I think thats how it's supposed to work .
The fear of dilution is real ...Co will need cash
JMO
Kiwi
👍️0
Whalatane Whalatane 4 weeks ago
Thx RMB. re In the study, 106 patients were enrolled, of which 86 patients entered titration and were followed as the Safety Population. Of the 86, 78 entered the maintenance period.
106 patients enrolled but only 78 made it to the maintenance period . This was a short trial so to lose roughly 25% of those enrolled fairly quickly ( for whatever reason ) raised questions on how well this drug would be received in the dialysis population .
The CC keeps being dropped as it's not conforming to my browser when I log in ...??? first time thats happened when I log into CC's.....so I wasn't able to follow all the Q & A
If you listen to the CC ...just skip to the Q & A portion

I'm not sure they were able to convincingly explain why they lost roughly 25% of the patients between enrollment and the maintenance phase. .....but as I said I wasn't able to access the entire Q & A

Kiwi
👍️0
rosemountbomber rosemountbomber 4 weeks ago
Ain’t that the truth. Bad enough when I guess wrong on the trial results, but to guess correctly and still get hammered. Sheesh.
👍️0
Mr.Mister Mr.Mister 4 weeks ago
Man,

Even when I "win" and guess right on clinical data I lose.

ARDX has been my only winner. Thought I could get lucky on UNCY. I guess too many warrants and fears of future dilution are keeping this down. Or maybe the warrant holders are shorting it
👍️0

Your Recent History

Delayed Upgrade Clock